Literature DB >> 3488743

Preparation and characterization of monoclonal antibodies to pregnenolone 16-alpha-carbonitrile inducible rat liver cytochrome P-450.

S S Park, D J Waxman, H Miller, R Robinson, C Attisano, F P Guengerich, H V Gelboin.   

Abstract

Hybridomas were prepared from mouse myeloma cells and spleen cells derived from BALB/c female mice immunized with purified rat hepatic pregnenolone 16-alpha-carbonitrile (PCN) induced cytochrome P-450 2a/PCN-E. The monoclonal antibodies (MAbs) thus obtained were screened for binding to the purified P-450 2a/PCN-E by radioimmunoassay. Eleven independent hybrid clones produced MAbs, each of which was of a single mouse immunoglobulin subclass of the IgG1, IgG2a or IgG2b type. Each of the MAbs produced by the eleven individual hybrid clones bound strongly to P-450 2a/PCN-E as assessed by radioimmunoassay and immunoprecipitation of P-450 2a/PCN-E in Ouchterlony double-immunodiffusion plates. Of the eleven MAbs, three also bound strongly to the phenobarbital-inducible rat liver cytochrome P-450 PB-4. Thus, two classes of MAbs were obtained, one class specific for P-450 2a/PCN-E and a second class that bound to both PCN- and phenobarbital-inducible P-450 forms. The reactivities of one MAb from each class toward eight highly purified rat hepatic cytochromes P-450 were examined using solid phase enzyme-linked immunosorbent analyses. The MAb designated C2 was found to be specific for P-450 2a/PCN-E and did not cross-react with seven other P-450 forms. This MAb was shown to be an effective probe for monitoring, by Western blotting, the induction of microsomal P-450 2a/PCN-E by PCN and phenobarbital. The MAb designated C1 reacted both with P-450 2a/PCN-E and with the two major phenobarbital-inducible P-450 forms, PB-4 and PB-5. None of the MAbs was inhibitory towards P-450 2a/PCN-E-dependent aryl hydrocarbon hydroxylase, benzphetamine N-demethylase, ethoxycoumarin O-deethylase or ethymorphine N-demethylase activity, indicating that the epitopes recognized by these MAbs are not directly associated with catalytic activity. The strong reactivities of three of the MAbs with both P-450 2a/PCN-E and P-450s PB-4 and PB-5 indicate that these two structurally quite different cytochrome P-450 families share at least one common epitope. These new MAbs are additions to our library of MAbs to different cytochromes P-450 and should help further our understanding of the relationship of cytochrome P-450 phenotype and multiplicity to inter-individual differences in drug and carcinogen metabolism and sensitivity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488743     DOI: 10.1016/0006-2952(86)90477-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Effects of acetysal, dexamethasone and their combination on drug metabolizing enzyme systems in rat liver microsomes.

Authors:  L P Tantcheva; D S Rangelova; T S Stoytchev
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

2.  Production and Characterization of Monoclonal Antibodies against NADPH-Cytochrome P-450 Reductases from Helianthus tuberosus.

Authors:  A Lesot; I Benveniste; M P Hasenfratz; F Durst
Journal:  Plant Physiol       Date:  1992-11       Impact factor: 8.340

3.  Hormonal regulation of the zonated expression of cytochrome P-450 3A in rat liver.

Authors:  T Oinonen; K O Lindros
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

4.  Monoclonal antibodies against human cytochrome P-450 recognizing different pregnenolone 16 alpha-carbonitrile-inducible rat cytochromes P-450.

Authors:  T S Barnes; P M Shaw; M D Burke; W T Melvin
Journal:  Biochem J       Date:  1987-11-15       Impact factor: 3.857

5.  Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis.

Authors:  Chi Chen; Yatrik M Shah; Keiichirou Morimura; Kristopher W Krausz; Makoto Miyazaki; Terrilyn A Richardson; Edward T Morgan; James M Ntambi; Jeffrey R Idle; Frank J Gonzalez
Journal:  Cell Metab       Date:  2008-02       Impact factor: 27.287

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.